Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous lignocaine versus fentanyl during percutaneous coronary intervention
ACTRN12619000648123Phase 3Completed
- Sponsor
- Alfred Health
- Start
- Feb 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lidocaine, fentanyl and ticagrelor in coronary arteriosclerosis (2 arms), sponsored by Alfred Health. Primary endpoint: Serum ticagrelor concentration. Started Feb 2020; status: completed.
02
Drugs
lidocainefentanylticagrelor
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ACTRN12619000648123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000648123.